The Board of Pharmacy has received notice of the following product recall:

Ranitidine Capsules, USP, 150mg

60 count bottles NDC number 70954-001-20

500 count bottles NDC number 70954-001-40

Batch numbers: S18035A (exp 10/20); S18035B (exp 10/20); S18036A (exp 10/20); S18036B (exp 10/20); S18037A (exp 10/20); S18037B (exp 10/20); M19173A (05/21); M19174A (05/21); M19236A (07/21);

and

Ranitidine Capsules, USP, 300mg

30 count bottles NDC number 70954-002-10

100 count bottles NDC number 70954-002-40

Batch numbers: S18038A (10/20); S18038B (exp 10/20); S18039A (exp 10/20); S18039B (exp 10/20); S18040A (exp 10/20); S18040B (exp 10/20); M19127A (exp 05/21); M19238A (exp 07/21).

Novitium Pharma is recalling the above product due the potential presence of N-Nitrosodimethylamine (NDMA) in the drug product above levels established by FDA. NDMA is classified as a probable human carcinogen (a substance that could cause cancer) based on results from laboratory tests. NDMA is a known environmental contaminant and found in water and foods, including meats, dairy products, and vegetables.

The Board of Pharmacy strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.